Thrivent Financial for Lutherans Sells 12,956 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Thrivent Financial for Lutherans cut its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 11.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 95,704 shares of the biopharmaceutical company’s stock after selling 12,956 shares during the period. Thrivent Financial for Lutherans owned 0.07% of Dynavax Technologies worth $1,066,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC boosted its position in Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,685 shares during the last quarter. US Bancorp DE raised its holdings in Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,034 shares during the last quarter. Capital Performance Advisors LLP acquired a new position in Dynavax Technologies during the 3rd quarter valued at about $45,000. Nisa Investment Advisors LLC boosted its stake in shares of Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,679 shares during the last quarter. Finally, Algert Global LLC acquired a new stake in shares of Dynavax Technologies during the 2nd quarter worth approximately $140,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on DVAX shares. The Goldman Sachs Group reduced their price objective on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. HC Wainwright restated a “buy” rating and issued a $29.00 price target on shares of Dynavax Technologies in a research report on Friday, November 8th.

Dynavax Technologies Stock Up 1.4 %

Dynavax Technologies stock opened at $13.04 on Tuesday. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $15.01. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of 100.32 and a beta of 1.34. The company’s 50 day simple moving average is $11.69 and its 200 day simple moving average is $11.40.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.